Immunotherapy III: Combinatorial molecular immunotherapy - A synthesis and suggestions

Cancer and Metastasis Reviews

Volumn 15, Issue 3, 1996, Pages 351-364

  Vile, Richard G ^a   Chong, Heung ^a  

^a ST THOMAS HOSPITAL   (United Kingdom)

Author keywords

antigen presentation; cytokines; gene therapy; immunotherapy

Indexed keywords

CANCER IMMUNOTHERAPY; GENE THERAPY; PRIORITY JOURNAL; REVIEW;

EID: 0029803117     PISSN: 01677659     EISSN: None     Source Type: Journal    
DOI: 10.1007/BF00046347     Document Type: Review

References (101)

1. Prehn RT: Two competing influences that may explain concomitant tumor resistance. Cancer Res 53: 3266-3269, 1993
2. Allione A, Consalvo M, Nanni P, Lollini PL, Cavallo F, Giovarelli M, Forni M, Gulino A, Colombo MP, Dellabona P, Hock H, Blankenstein T, Rosenthal FM, Gansbacher B, Bosco MC, Musso T, Gusella L, Forni G: Immunizing and curative potential of replicating and nonreplicating murine mammary adenocarcinoma cells engineered with Interleukin (IL)- 2, IL-4, 1L-6, IL-7, IL-10, tumour necrosis factor alpha, granulocyte-macrophage colony-stimulating factor, and gamma interferon gene or admixed with conventional adjuvants. Cancer Res 54: 6022-6026, 1994
3. Hock H, Dorsch M, Kunzendorf U, Uberla K, Qin Z, Diamantstein T, Blankenstein T: Vaccinations with tumor cells genetically engineered to produce different cytokines: effectivity not superior to a classical adjuvant. Cancer Res 53: 714-716, 1993
4. Dranoff G, Jaffee E, Lazenby A, Golumbek P, Levitsky H, Brose K, Jackson V, Hamada H, Pardoll D, Mulligan RC: Vaccination with irradiated tumor cells engineered to secrete murine granulocyte macrophage colony stimulating factor stimulates potent, specific, and long lasting anti-tumor immunity. Proc Nat Acad Sci USA 90: 3539-3543, 1993
5. Forni G, Cavallo F, Consalvo M, Allione A, Dellabona P, Casorati G, Giovarelli M: Molecular approaches to cancer immunotherapy. Cytokines and Molecular Therapy 1: 225-248, 1995
6. Pardoll DM: Paracrine Cytokine Adjuvants in Cancer Immunotherapy. Ann Rev Immunol 13: 399-415, 1995
7. Tepper RI, Mule JJ: Experimental and clinical studies of cytokine gene-modified tumor cells. Hum Gene Ther 5: 153-164, 1994
8. Cayeux S, Beck C, Aicher A, Dorken B, Blankenstein T: Tumor cells cotransfected with interleukin-7 and B7.1 genes induce CD25 and CD28 on tumor-infiltrating T lymphocytes and are strong vaccines. Eur J Immunol 25: 2325-2331, 1995
9. Townsend SE, Su FW, Atherton JM, Allison JP: Specificity and longevity of antitumor immune responses induced by B7-transfected tumors. Cancer Res 54: 6477-6483, 1994
10. Matulonis U, Dosiou C, Freeman G, Lamont C, Mauch P, Nadler LM, Griffin JD: B7-1 is superior to B7-2 costimulation in the induction and maintenance of T cell-mediated antileukemia immunity. J Immunol 156: 1126-1131, 1996
11. Cavallo F, Giovarrelli M, Gulino A, Vacca A, Stoppacciaro A, Modesti A, Forni G: Role of neutrophils and CD4 + T lymphocytes in the primary and memory response to non immunogenic murine mammary adenocarcinoma made immunogenic by IL-2 gene transfer. J Immunol 149: 3627-3635, 1992
12. Santodonato L, Ferrantini M, Gabriele L, Proietti E, Venditti M, Musiani P, Modesti A, Modica A, Lupton SD, Belardelli F: Cure of mice with established metastatic friend leukemia cell tumors by a combined therapy with tumor cells expressing both interferon al and herpes simplex thymidine kinase followed by ganciclovir. Hum Gene Ther 7: 1-10, 1996
13. Addison CL, Gauldie J, Muller WJ, Graham FL: An adenoviral vector expressing interleukin-4 modulates tumorigenicity and induces regression in a murine breast cancer model. Intern J Oncol 7: 1253-1260, 1995
14. Pericle F, Giovarelli M, Colombo MP, Ferrari G, Musiani P, Modesti A, Cavallo F, Di Pierro F, Novelli F, Forni G: An efficient Th2-type memory follows CD8 + lymphocyte-driven and eosinophil-mediated rejection of a spontaneous mouse mammary adenocarcinoma engineered to release IL-4 +. Amer Assoc Immunol 5659-5673, 1994
15. Colombo MP, Forni G: Cytokine gene transfer in tumor inhibition and tumor therapy: where are we now? Immunol Today 15: 48-51, 1994
16. Cavallo F, Di Pierro F, Giovarrelli M, Gulino A, Vacca A, Stoppacciaro A, Forni M, Modesti A, Forni G: Protective and curative potential of vaccination with interleukin-2-gene transfected cells from a spontaneous mouse mammary adenocarcinoma. Cancer Res 53: 5057-5070, 1993
17. Townsend SE, Allison JP: Tumour rejection after direct costimulation of CD8 + T cells by B7-transfected melanoma cells. Science 259: 368-370, 1993
18. Moolten FL: Drug sensitivity ('suicide') genes for selective cancer chemotherapy. Cancer Gene Ther 1: 279-287, 1994
19. Miller N, Vile RG: Targeted vectors for gene therapy. FASEB J 9: 190-199, 1995
20. Jolly D: Viral vector systems for gene therapy. Cancer Gene Ther 1: 51-64, 1994
21. Vile RG, Russell SJ: Gene transfer technologies for the gene therapy of cancer. Gene Ther 1: 88-98, 1994
22. Parmiani G: Tumor immunity as autoimmunity: tumor antigens include normal self proteins which stimulate anergic peripheral T cells. Immunol Today 14: 536-538, 1993
23. Van Pel AVDB, Coulie PG, Brichard VG, Lethe B, Van den Eynde B, Uttenhove C, Renauld J-C, Boon T: Genes coding for tumour antigens recognised by cytolytic T lymphocytes. Immunol Rev 145: 229-250, 1995
24. Houghton AN: Cancer antigens: immune recognition of self and altered self. J Exp Med 180: 1-4, 1994
25. Pardoll DM: Tumor antigens: a new look for the 1990s. Nature 369: 357-358, 1994
26. Vile RG, Chong HC, Dorudi S: Immunosurveillance of cancer: specific and non-specific mechanisms. Tumour Immunology. Cambridge University Press (Dalgleish, AG and Browning MJ) In Press: 7-38, 1996
27. Dalgleish A: The case for therapeutic vaccines. Melanoma Res 6: 5-10, 1996
28. Morton DL, Foshag LJ, Hoon DSB, Nizze JA, Wanek LA, Chang C, Davtyan DG, Gupta RK, Elashoff R, Irie RF: Prolongation of survival in metastatic melanoma after active specific immunotherapy with a new polyvalent melanoma vaccine. Ann Surg 216: 463-482, 1993
29. Morton DL, Hoon DSB, Nizze J et al: Polyvalent melanoma vaccine improves survival of patients with metastatic melanoma. Ann NY Acad Sci 690: 120-134, 1993
30. Nabel GJ, Chang A, Nabel EG, Plautz G, Fox BA, Huang L, Shu S: Clinical Protocol: Immunotherapy of malignancy by in vivo gene transfer into tumors. Hum Gene Ther 3: 399-410, 1992
31. Plautz GE, Yang Z-Y, Wu B-Y, Gao X, Huang L, Nabel GJ: Immunotherapy of malignancy by in vivo gene transfer into tumors. Proc Nat Acad Sci USA 90: 4645-4649, 1993
32. Nabel GJ, Nabel EG, Yang ZY, Fox BA, Plautz GE, Gao X, Huang L, Shu S, Gordon D, Chang AE: Direct gene transfer with DNA-liposome complexes in melanoma: expression, biologic activity, and lack of toxicity in humans. Proc Nat Acad Sci USA 90: 11307-11311, 1993
33. Barba D, Hardin J, Sadelain M, Gage FH: Development of anti tumor immunity following thymidine kinase-mediated killing of experimental brain tumors. Proc Nat Acad Sci USA 91: 4348-4352, 1994
34. Caruso M, Panis Y, Gagandeep S, Houssin D, Salzmann JL, Klatzmann D: Regression of established macroscopic liver metastases after in situ transduction of a suicide gene. Proc Nat Acad Sci USA 90: 7024-7028, 1993
35. Mullen CA, Coale MM, Lowe R, Blaese RM: Tumors expressing the cytosine deaminase suicide gene can be eliminated in vivo with 5-fluorocytosine and induce protective immunity to wild type tumor. Cancer Res 54: 1503-1506, 1994
36. Consalvo M, Mullen CA, Modesti A, Musiani P, Allione A, Cavallo F, Giovarelli M, Forni G: 5-fluorocytosine-induced eradication of murine adenocarcinomas engineered to express the cytosine deaminase suicide gene requires host immune competence and leaves an efficient memory. J Immunol 154: 5302-5312, 1995
37. Vile RG, Nelson JA, Castleden SC, Chong H, Hart IR: Systemic gene therapy of murine melanoma using tissue specific expression of the HSVtk gene involves an immune component. Cancer Res 54: 6228-6234, 1994
38. Kaneko Y, A T: Gene therapy of hepatoma: bystander effects and non-apoptotic cell death induced by thymidine kinase and ganciclovir. Cancer Lett 96: 105-110, 1995
39. Samejima Y, Meruelo D: 'Bystander killing' induces apoptosis and is inhibited by forskolin. Gene Ther 2: 50-58, 1995
40. Freeman SM, Abboud CN, Whartenby KA, Packman CH, Koeplin DS, Moolten FL, Abraham GN: The 'bystander effect': tumor regression when a fraction of the tumor mass is genetically modified. Cancer Res 53: 5274-5283, 1993
41. Wyllie AH: Apoptosis (The 1992 Frank Rose Memorial Lecture). Brit J Cancer 67: 205-208, 1993
42. Fisher DE: Apoptosis in Cancer Therapy: Crossing the Threshold. Cell 78: 539-542, 1994
43. Colombo MP, Modesti A, Parmiani G, Forni G: Local cytokine availability elicits tumor rejection and systemic immunity through granulocyte-T-lymphocyte cross-talk. Cancer Res 52: 4853-4857, 1992
44. Restifo NP, Esquivel F, Kawakami Y, Yewdell JW, Mule JJ, Rosenberg SA, Bennink JR: Identification of human cancers deficient in antigen processing. J Exp Med 177: 265-272, 1993
45. Huang AYC, Bruce AT, Pardoll DM, Levitsky HI: Does B7-1 expression confer antigen-presenting cell capacity to tumors in vivo? J Exper Med 183: 709-776, 1996
46. Huang AYC, Golumbek P, Ahmadzadeh M, Jaffee E, Pardoll D, Levitsky H: Role of bone marrow derived cells in presenting MHC Class I-restricted tumor antigens. Science 264: 961-965, 1994
47. Steinman RM: The dentritic cell system and its role in immunogenicity. Ann Rev Inc 271-296, 1991
48. Grabbe S, Beissert S, Schwarz T, Granstein RD: Dendritic cells as initiator of tumor immune responses: a possible strategy for tumor immunotherapy? Immunol Today 16: 117-121, 1995
49. Levitsky HI, Lazenby A, Hayashi RJ, Pardoll D: In vivo priming of two distinct antitumor effector populations: The role of MHC Class I expression. J Exp Med 179: 1215-1224, 1994
50. Guo Y, Wu M, Chen H, Wang X, Liu G, Li G, Ma J, Sy M-S: Effective tumor vaccine generated by fusion of hepatoma cells with activated B cells. Science 263: 518-520, 1994
51. Pecher G, Finn OJ: Induction of cellular immunity in chimpanzees to human tumor-associated antigen mucin by vaccination with MUC-1 cDNA-transfected Epstein-Barr virus-immortalized autologous B cells. Proc Natl Acad Sci USA 93: 1699-1704, 1996
52. Kundig TM, Backmann MF, DiPaolo C, Simard JJL, Battegay M, Lother H, Gessner A, Kuhlcke K, Ohashi PS, Hengartner H, Zinkernagel RM: Fibroblasts as efficient antigen-presenting cells in lymphoid organs. Science 268: 1343-1347, 1995
53. Bright RK, Beames B, Shearer MH, Kennedy RC: Protection against a lethal tumor challenge with SV40-transformed cells by the direct injection of DNA-encoding SV40 large tumor antigen. Cancer Res 56: 1126-1130, 1996
54. Hawkins RE, Winter G, Hamblin TJ, Stevenson FK, Russell SJ: A genetic approach to idiotypic vaccination. J Immunol (In Press): 1993
55. Wang B, Merva M, Dang K, Ugen KE, Williams WV, Weiner DB: Immunization by direct inoculation induces rejection of tumor cell challenge. Human Gene Ther 6: 407-418, 1995
56. Ulmer JB, Donnelly JJ, Parker SE, Rhodes GH, Felgner PL, Dwarki VJ, Gromkowski SH et al.: Heterologous protection against influenza by injection of DNA encoding a viral protein. Science 259: 1745-1749, 1993
57. Pardoll DM, Beckerleg AM: Exposing the immunology of naked DNA vaccines. Immunity 3: 165-169, 1995
58. Raychaudhuri S, Morrow WJW: Can soluble antigens induce CD8 + cytotoxic T cell responses? A paradox revisited. Immunol Today 14: 344-348, 1993
59. Hess J, Gentschev I, Miko D, Welzel M, Ladel C, Goebel W, Kaufmann SHE: Superior efficacy of secreted over somatic antigen display in recombinant Salmonella vaccine induced protection against listeriosis. Immunol 93: 1458-1463, 1996
60. Bellone M, Iezzi G, Manfredi A, Dellabona P, Casorati G, Rugarli C: In vitro priming of cytotoxic T lymphocytes against poorly immunogenic epitopes by engineered antigen-presenting cells. Eur J Immunol 24: 2691-2698, 1994
61. Flamand V, Sornasse T, Thielemans K, Demanet C, Bakkus M, Bazin H, Tielemans F, Leo O, Urbain J, Moser M: Murine dendritic cells pulsed in vitro with tumor antigen induce tumor resistance in vivo. Eur J Immunol 24: 605-610, 1994
62. Mayordomo JI, Zorina T, Storkus WJ, Zitvogel L, Celluzzi C, Falo LD, Melief CJ, Ildstad ST, Kaast WM, Deleo AB, Lotze MT: Bone marrow-derived dendritic cells pulsed with synthetic tumour peptide elicit protective and therapeutic antitumor immunity. Nat Med 1: 1297-1302, 1995
63. Porgador A, Gilboa E: Bone marrow-generated dendritic cells pulsed with a class I-restricted peptide are potent inducers of cytotoxic T lymphocytes. J Exp Med 182: 255-260, 1995
64. Zitvogel LJ, Mayordomo I, Tjanddrawan T, DeLeo AB, Clarke MR, Lotze MT, Storkus WJ: Therapy of murine tumors with tumor-specific peptide pulsed dendritic cells: dependence on T cells, B7 costimulation and Th1 associated cytokines. J Exp Med 183: 87-97, 1996
65. Young JW, Inaba K: Dendritic cells as adjuvants for Class 1 major histocompatibility complex-restricted antitumor immunity. J Exp Med 183: 7-11, 1996
66. Hock H, Dorsch M, Kunzendorf U, Qin Z, Diamantstein T, Blankenstein T: Mechanisms of rejection induced by tumor cell-targeted gene transfer of interleukin-2, interleukin-4, interleukin 7, tumor necrosis factor, or interferon gamma. Proc Natl Acad Sci USA 90: 2774-2778, 1993
67. Giovarelli M, Musiani P, Modesti A, Dellabona P, Casorati G, Allione A, Consalvo M, Cavallo F, di Pierro F, De Giovanni C, Musso T, Forni G: Local release of IL-10 by transfected mouse mammary adenocarcinoma cells does not suppress but enhances antitumor reaction and elicits a strong cytotoxic lymphocyte and antibody-dependent immune memory. Amer Assoc Immunol 3112-3123, 1995
68. Porgador A, Gansbacher B, Bannerji R, Tzehoval E, Gilboa E, Feldman M, Eisenbach L: Anti-metastatic vaccination of tumour bearing mice with IL-2-gene-inserted tumour cells. Int J Cane 53: 471-477, 1993
69. Connor J, Bannerji R, Saito S, Heston W, Fair W, Gilboa E: Regression of bladder tumors in mice treated with interleukin-2 gene-modified tumor cells. J Exp Med 117: 1127-1134, 1993
70. Visseren MJW, Koot KM, van der Voort E et al.: Production of interleukin-2 by EL-4 tumor cells induces natural killer cell- and T-cell mediated immunity. J Immunother 15: 119-128, 1994
71. Karp SE, Farber A, Salo JC, Hwu P, Jaffe G, Asher AL, Shiloni E, Restifo NP, Mule JJ, Rosenberg SA: Cytokine secretion by genetically modified non-immunogenic murine fibrosarcoma. J Immunol 150: 896-908, 1993
72. Schmidt W, Schweighoffer T, Herbst E, Maass G, Berger M, Schilcher F, Schaffner G, Birnstiel ML: Cancer vaccines: the interleukin 2 dosage effect. Proceedings of the Nat Acad Sci USA 92: 4711-4714, 1995
73. Fakhrai H, Shawler DL, Gjerset R, Naviaux RK, Koziol J, Royston I, Sobol RE: Cytokine gene therapy with interleukin-2-transduced fibroblasts: effects of IL-2 dose on anti-tumor immunity. Hum Gene Ther 6: 591-601, 1995
74. Seung LP, Seung SK, Schrieber H: Antigenic cancer cells that escape immune destruction are stimulated by host cells. Cancer Res 55: 5094-5100, 1995
75. Prehn RT: Stimulatory effects of immune reactions upon the growths of untransplanted tumors. Cancer Res 54: 908-914, 1994
76. Foa R, Guarini A, Gansbacher B: IL-2 treatment for cancer: from biology to gene therapy. Brit J Cane 66: 992-998, 1992
77. Inaba K, Inaba M, Romani M et al.: Generation of large numbers of dendritic cells from mouse bone marrow cultures supplemented with granulocyte macrophage colony stimulating factor. J Exp Med 176: 1693-1702, 1992
78. Berns AJ et al.: Clinical protocol: Phase I study of non-replicating autologous tumor cell injections using cells prepared with or without GM-CSF gene transduction in patients with metastatic renal cell carcinoma. Hum Gene Ther 347-368, 1995
79. Saito S, Bannerji R, Gansbacher B, Rosenthal FM, Romanenko P, Heston WDW, Fair WR, Gilhoa E: Immunotherapy of bladder cancer with cytokine gene modified tumor vaccines. Cancer Res 54: 3516-3520, 1994
80. Stoppacciaro A, Melani C, Parenza M, Matracchio A, Bassi C, Baroni C, Parmiani G, Colombo MP: Regression of an established tumor genetically modified to release granulocyte colony-stimulating factor requires granulocyte-T cell cooperation and T cell-produced interferon gamma. J Exp Med 178: 151-161, 1993
81. Carducci MA, Ayyagari SR, Sanda MG, Simons JW: Gene therapy for human prostate cancer. Cancer 75: 2013-2020, 1995
82. Vieweg J, Rosenthal FM, Bannerji R, Heston WDW, Fair WR, Gansbacher B, Gilboa E: Immunotherapy of prostate cancer in the Dunning rat model: use of cytokine gene modified tumor vaccines. Cancer Res 54: 1760-1765, 1994
83. Abe J, Wakimoto H, Yoshida Y, Aoyagi M, Hirakawa K, Hamada H: Antitumor effect induced by granulocyte/macrophage-colony-stimulating factor gene-modified tumor vaccination: comparison of adenovirus- and retrovirus-mediated genetic transduction. J Cancer Res Clin Oncol 121: 587-592, 1995
84. Dallman MJ: Cytokines and transplantation: Th1/Th2 regulation of the immune response to solid organ transplants in the adult. Current Opin Immunol 7: 632-638, 1995
85. Kelso A: Th1 and Th2 subsets: paradigms lost? Immunol Today 16: 374-379, 1995
86. Paul WE, Seder RA: Lymphocyte responses and cytokines. Cell 76: 241-251, 1994
87. Tahara H, Lotze MT: Antitumor effects of interleukin-12 (IL-12): applications for the immunotherapy and gene therapy of cancer. Gene Ther 2: 96-106, 1995
88. Tahara H, Zitvogel L, Strokus WJ, Zeh III HJ, McKinney TG, Schreiber RD, Gubler U, Robbins PD, Lotze MT: Effective eradication of established murine tumors with IL-12 gene therapy using a polycistronic retroviral vector. J Immunol 6466-6474, 1995
89. Banks RE, Patel PM, Selby PJ: Interleukin 12: a new clinical player in cytokine therapy. Brit J Cancer 71: 655-659, 1995
90. Gerard CM, Bruyns C, Delavaux A, Baduson N, Dargent J-L, Goldman M, Velu T: Loss of tumorigenicity and increased immunogenicity induced by interleukin-10 gene transfer in B16 melanoma cells. Hum Gene Ther 7: 11-22, 1996
91. Vile RG: Tumour specific gene expression. In: Collins MKL (ed) Seminars in Cancer Biology 5: 429-436, 1994
92. Chen S-H, Chen XHL, Wang Y, Kosai K-I, Finegold MJ, Rich SS, Woo SLC: Combinalion gene therapy for liver metastasis of colon carcinoma in vivo. Proc Nat Acad Sci USA 92: 2577-2581, 1995
93. Morgan RA, Couture L, Elroy-Stein O, Ragheb J, Moss B, French Anderson W: Retroviral vectors containing putative internal ribosome entry sites: development of a polycistronic gene transfer system and aplications to human gene therapy. Nucl Acids Res 20: 1292-1299, 1992
94. Frebourg T, Sadelain M, Ng Y-S, Kassel J, Friend SH: Equal transcription of wild-type and mutant p53 using bicistronic vectors results in the wild-type phenotype. Cancer Res 54: 878-881, 1994
95. Hellstrom KE, Hellstrom I, Chen L: Can co-stimulated tumor immunity be therapeutically efficacious? Immunol Rev 145: 135-145, 1995
96. Browning MJ, Bodmer WF: MHC antigens and cancer: implications for T-cell surveillance. Curr Opin Immunol 4 613-618, 1992
97. Udono H, Levey DL, Srivastava PK: Cellular requirements for tumor-specific immunity elicited by heat shock proteins: tumor rejection antigen gp96 primes CD8 + cells in vivo. Proc Nat Acad Sci USA 91: 3077-3081, 1994
98. Kim TS, Cohen EP: Interleukin-2 secreting mouse fibroblasts transfected with genomic DNA from murine melanoma cells prolong the survival of mice with melanoma. Cancer Res 54: 2531-2535, 1994
99. Russell SJ, Eccles SA, Flemming CL, Johnson CA, Collins MKL: Decreased tumorigenicity of a transplantable rat sarcoma following transfer and expression of an IL-2 cDNA. Int J Cancer 47: 244-251, 1991
100. Neefjes JJ, Momburg F: Cell biology of antigen presentation. Curr Opin Immunol 5: 27-34, 1993
101. Powis SH, Geraghty DE: What is the MHC? Immunol Today: 16: 464-468, 1995